Clinical trials: Head and Neck Disorder
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN)
TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to learn if an experimental, personalized cancer vaccine called TMV vaccine is safe and to find the best dose to study in future trials.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence, Local
- Trial name
- NCT07898124
- Testing
- TMV Vaccine, Toripalimab-tpzi
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Metaclipse Therapeutics Corporation
Esophageal Squamous Cell Carcinoma
Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）
Based on our previous single-arm Phase Ib study (CRIS trial, NCT06303583), we observed that neoadjuvant chemoradiotherapy followed by immunotherapy (nCRIT) significantly increased the pathological complete response (pCR) rate…
- Trial name
- NCT06509568
- Testing
- Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
This is an exploratory study to evaluate the safety and preliminary effectiveness of BGT007 cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma
- Trial name
- NCT05616468
- Testing
- BGT007 Cell Injection, Fludarabine, cyclophosphamide
- Where
- China
- Volunteers
- 23 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Esophageal Neoplasm, Gastric Neoplasm
Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer
The prognosis for patients with advanced oesophago-gastric cancer is poor. Approximately 16,000 patients in the United Kingdom die from the disease.
- Trial name
- NCT01870791
- Testing
- Omegaven
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University Hospitals, Leicester
Mucositis, Xerostomia
Effectiveness of Photobiomodulation Protocols in Radiation-induced Oral Side Effects in H&N Cancer Patients
Head and neck cancer (HNC) are among the most frequent malignancies in the world. The main treatment modalities for HNC are surgical excision, radiotherapy (RT), and chemotherapy (CT).
- Conditions
- Mucositis, Xerostomia, Hyposalivation
- Trial name
- NCT05242991
- Testing
- Photobiomodulation therapy
- Where
- Brazil
- Volunteers
- 132 people
- Sponsor
- Federal University of Rio Grande do Sul
Gastric Cancer, Esophageal Cancer
Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer
In this study, patients with adenocarcinoma of the stomach, gastro-esophageal junction or the distal esophagus who seem operable with curative intent according to oncological and surgical assessment are treated with 3…
- Trial name
- DCXAIOCHARITE (NCT00865982)
- Testing
- Docetaxel, Cisplatin, Capecitabine
- Where
- 9 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Charite University, Berlin, Germany
Oropharyngeal Cancer, Human Papilloma Virus
Men and Women Offering Understanding of Throat HPV
This study will screen people for oncogenic oral Human Papillomavirus (HPV) infection and antibodies to form a cohort of people who may be at increased risk of HPV-oropharyngeal cancer (HPV-OPC).
- Trial name
- MOUTH (NCT03644563)
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Head and Neck Cancer, Recurrent Cancer
Postoperative Complication After Free Flap Reconstruction for Head and Neck Cancer
This study was designed to investigate the outcome of free-flap reconstruction surgery following head and neck cancer resection between primary and recurrent head and neck cancer patients.
- Conditions
- Head and Neck Cancer, Recurrent Cancer, Surgery--Complications
- Trial name
- NCT04326088
- Testing
- Reconstruction group, Recurrent group
- Where
- Taiwan
- Volunteers
- 2,004 people
- Sponsor
- Chang Gung Memorial Hospital
Non-small Cell Lung Cancer, Hepatocellular Carcinoma
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe…
- Conditions
- Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03916627
- Testing
- cemiplimab, Platinum Doublet, fianlimab
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteer, Prostate Cancer
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes.
- Conditions
- Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer
- Trial name
- NCT04354064
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Oral Squamous Cell Carcinoma (OSCC), Premalignant Lesion
Comparison of TLC (Total Leucocyte Count), Neutrophils and Monocytes in Oral Squamous Cell Carcinoma and Pre-malignant Disorders
Oral squamous cell carcinoma is one of the significant public health concerns and the most prevalent malignancies affecting the head and neck region globally.
- Trial name
- NCT07899255
- Testing
- CBC will be required to assess the level of TLC (Total Leucocyte Count), Neutrophils and Monocytes in patient of oral squamous cell carcinoma and oral pre malignant conditions, using different stains
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Dow University of Health Sciences
Barrett Esophagus, Esophageal Cancer
Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus
Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions when presented with different…
- Trial name
- NCT05846971
- Testing
- Educational materials on validated methylation assay
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Capsulomics, Inc.
Cervical Intraepithelial Neoplasia, Cervical Neoplasms
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Background: Gene therapy is closely followed by the U.S. Food and Drug Administration (FDA). The FDA requires researchers to conduct long-term follow-up of people who have had the treatment.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Neoplasms, Oropharyngeal Neoplasms, Squamous Intraepithelial Lesions of the Cervix
- Trial name
- NCT04266093
- Testing
- GeneTherapy
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.
To assess the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (with symptomatic dysphagia or oligometastatic…
- Trial name
- NCT06464614
- Testing
- Adebrelimab, Apatinib, Investigator chosen chemotherapy (ICC)
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Cancer
Mechanistic Study on the Diagnosis of Esophageal Cancer Lymph Node Metastasis Using Spectral CT, Multimodal MRI, FAPI PET-CT, Pathology, and AI Evaluation System
The objective of this study is to address the urgent issues in the diagnosis of lymph node metastasis in esophageal cancer. By employing multimodal MRI, spectral CT imaging and FAPI PET-CTtechniques, the study will correlate…
- Trial name
- NCT06818214
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Henan Cancer Hospital
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies
- Conditions
- Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer
- Trial name
- NCT06052852
- Testing
- BDC-3042, Cemiplimab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Esophageal Cancer, Squamous Cell
Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia
In recent years, endocytoscopy (EC) has undergone rapid development as an advanced endoscopic technique. Characterized by real-time histological imaging and detection capabilities, EC enables visualization of living cells in the…
- Trial name
- NCT06984055
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Changhai Hospital
Locally Advanced Esophageal Squamous Cell Carcinoma
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if cadonilimab combined with anlotinib can be a safe and effective neoadjuvant therapy in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06426797
- Testing
- Cadonilimab plus anlotinib
- Volunteers
- 25 people
- Sponsor
- Peking University People's Hospital
Thyroid Carcinoma
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
This is a non-interventional, multi center post-authorization safety study that includes all patients diagnosed as Unresectable Differentiated Thyroid Carcinoma (DTC) and treated with Sorafenib within a certain period.
- Trial name
- JPMS-DTC (NCT02185560)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 453 people
- Sponsor
- Bayer